News Image

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Provided By PR Newswire

Last update: Apr 22, 2024

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis

Novel Redirected Soluble Modulator technology has demonstrated the potential to enhance immune receptor signaling

Read more at prnewswire.com

CARISMA THERAPEUTICS INC

NASDAQ:CARM (2/21/2025, 8:05:14 PM)

Premarket: 0.4638 +0.01 (+3.02%)

0.4502

-0.01 (-2.7%)



Find more stocks in the Stock Screener

Follow ChartMill for more